Repository logo
 

Latest Advances in Aging Research and Drug Discovery

Published version
Peer-reviewed

Type

Article

Change log

Authors

Abstract

An increasing aging population poses a significant challenge to societies worldwide. A better understanding of the molecular, cellular, organ, tissue, physiological, psychological, and even sociological changes that occur with aging is needed in order to treat age-associated diseases. The field of aging research is rapidly expanding with multiple advances transpiring in many previously disconnected areas. Several major pharmaceutical, biotechnology, and consumer companies made aging research a priority and are building internal expertise, integrating aging research into traditional business models and exploring new go-to-market strategies. Many of these efforts are spearheaded by the latest advances in artificial intelligence, namely deep learning, including generative and reinforcement learning. To facilitate these trends, the Center for Healthy Aging at the University of Copenhagen and Insilico Medicine are building a community of Key Opinion Leaders (KOLs) in these areas and launched the annual conference series titled “Aging Research and Drug Discovery (ARDD)” held in the capital of the pharmaceutical industry, Basel, Switzerland (www.agingpharma.org). This ARDD collection contains summaries from the 6th annual meeting that explored aging mechanisms and new interventions in age-associated diseases. The 7th annual ARDD exhibition will transpire 2nd-4th of September, 2020, in Basel.

Description

Keywords

aging, artificial intelligence, drug discovery, Aging, Drug Discovery, Drug Industry, Humans, Research

Journal Title

Aging

Conference Name

Journal ISSN

1945-4589
1945-4589

Volume Title

11

Publisher

Impact Journals
Sponsorship
DB is supported by the German Research Foundation (Forschungsstipendium; BA 6276/1-1) and the Lundbeckfonden (#R303-2018-3159). DC is funded by the NIH (R01AG 063389, R01AG063404, R01DK117481, R01DK101885) and the NIFA. VNG is supported by NIH grants. AT is supported by the Russian Federation grant 14.W03.31.0012. TH is supported by the Deutsche Forschungsgemeinschaft (DFG) (CECAD) and the European Research Council (consolidator grant 616499). DCR is grateful for funding from the UK Dementia Research Institute (funded by the MRC, Alzheimer’s Research UK and the Alzheimer’s Society) (DCR), an anonymous donation to the Cambridge Centre for Parkinson-Plus, The Rosetrees Trust, The Tau Consortium and The Roger de Spoelberch Foundation (DCR). MSK is funded by the Nordea Foundation (#02-2017-1749), the Novo Nordisk Foundation (#NNF17OC0027812), the Danish Cancer Society (#R167-A11015_001), the Independent Research Fund Denmark (#7016-00230B), the Neye Foundation and Insilico Medicine.